Live tape
Top 8, mentions 7d10,080TSLA2,070 mentions▲ +0.05GOOGL1,610 mentions▲ +0.04NVDA1,232 mentions▲ +0.07CRWV1,218 mentions▲ +0.03SPCX1,107 mentions▲ +0.07QQQ1,076 mentions▲ +0.04META891 mentions▲ +0.05NBIS876 mentions▲ +0.05

Equity · Healthcare

CTNM

NASDAQ

Contineum Therapeutics, Inc.

$9 −32.79% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 12, 2026
Price · Chart
17 sessions
$16 $8 21 Jul 12 Oct

The line runs $13.90 on 21 July through $9 on 12 October, on a scale from $8 to $16. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 17 sessions, 21 Jul – 12 Oct 2026
Market cap $207.9M
52-week range $9 – $16
Avg volume 70.9K

as of Oct 12, 2026

CTNM insider trades

SEC Form 4 · last 90 days · newest reported trade 8 Sep 2026
Open-market buys 0
Open-market sells 2
Net sold $81K
Non-trade filings 2
Date Insider Type Shares Value
08 Sep 2026 Stengone Carmine N. CEO and President Sell 2,500 $41K
03 Aug 2026 Stengone Carmine N. CEO and President Sell 2,500 $40K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Sep 2026 Stengone Carmine N. CEO and President Option exercise 2,500 $3K
03 Aug 2026 Stengone Carmine N. CEO and President Option exercise 2,500 $3K

CTNM reported financials

SEC EDGAR XBRL SEC EDGAR

CTNM reported net income of −$60.0M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$60.0M 31 Dec 2025 fiscal year
Diluted EPS −$2.17 31 Dec 2025 fiscal year
Total assets $250.4M 30 Jun 2026 at period end
Total equity $239.7M 30 Jun 2026 at period end

CTNM earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.40 —
31 Mar 2026 Q1 2026 −$0.39 —
31 Dec 2025 FY 2025 −$2.17 —
30 Jun 2025 Q2 2026 −$0.62 —
31 Mar 2025 Q1 2026 −$0.62 —
31 Dec 2024 FY 2024 −$2.18 —
30 Sep 2024 Q3 2024 −$0.40 —
30 Jun 2024 Q2 2024 −$0.39 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

CTNM institutional holders

SEC Form 13F SEC EDGAR

7 of the 45 institutional funds we track reported a CTNM position for the quarter ended 30 Jun 2026 — a combined $50.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Balyasny Asset Management Held (±25%) −9.7% shares 1,522,793 $25.0M
Millennium Management Trimmed −39.3% shares 931,709 $15.3M
Citadel Advisors Held (±25%) +13.2% shares 396,354 $6.5M
Marshall Wace Trimmed −47.8% shares 118,058 $1.9M
Renaissance Technologies Held (±25%) −3.0% shares 67,300 $1.1M
Two Sigma Investments Held (±25%) −20.0% shares 30,347 $497K
Point72 Asset Management Trimmed −69.6% shares 25,779 $423K
Baker Bros. Advisors Exited

CTNM fails-to-deliver

SEC CNS data SEC

On 22 Sep 2026, 32 shares of CTNM failed to deliver (about $434).

Settlement date Shares failed Notional % of shares out
22 Sep 2026 32 $434 <0.001%
15 Sep 2026 2,695 $40K 0.012%
04 Sep 2026 40 $703 <0.001%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings